Lataa...
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agn...
Tallennettuna:
| Julkaisussa: | J Immunother Cancer |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5950135/ https://ncbi.nlm.nih.gov/pubmed/29754585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0342-x |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|